BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Blood

• Publication date

  2002-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V100.12.3935PMID 12433696
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• World Health Organization Classification of Tumours

  2002cited by this paper
• Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.

  2001cited by this paper
• Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma.

  2001cited by this paper
• Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.

  2001cited by this paper
• Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.

  2000cited by this paper
• Clinical drug‐resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl‐2 expression in the surrounding lymphocytes and with increased bcl‐2 expression in the Reed–Sternberg cells

  2000cited by this paper
• Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity.

  2000cited by this paper
• Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.

  2000influential reference
• EBVD Combination Chemotherapy Plus Low Dose Involved Field Radiation is a Highly Effective Treatment Modality for Early Stage Hodgkin's Disease

  2000cited by this paper
• Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in hodgkin's disease, the Milan Cancer Institute Experience

  2000cited by this paper
• Poor clinical outcome of patients with Hodgkin's Disease and elevated interleukin-10 serum levels

  2000cited by this paper
• Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.

  2000cited by this paper
• Bcl-2 family proteins as targets for anticancer drug design

  2000cited by this paper
• Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.

  1999cited by this paper
• Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.

  1999cited by this paper
• The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease.

  1998cited by this paper
• Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.

  1998cited by this paper
• A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

  1998cited by this paper
• Single-cell analysis of the t(14;18)(q32;q21) chromosomal translocation in Hodgkin's disease demonstrates the absence of this translocation in neoplastic Hodgkin and Reed-Sternberg cells.

  1998cited by this paper
• The Bcl-2 protein family: arbiters of cell survival.

  1998cited by this paper
• Cytogenetics of Hodgkin’s disease

  1998cited by this paper
• Clonality in nodular lymphocyte-predominant Hodgkin's disease.

  1997cited by this paper
• Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

  1997cited by this paper
• Prognosis of patients with advanced hodgkin's disease

  1997cited by this paper
• Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.

  1997cited by this paper
• Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease.

  1996cited by this paper
• Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells

  1996cited by this paper
• Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.

  1996cited by this paper
• Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.

  1996cited by this paper
• Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma

  1996cited by this paper
• Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).

  1996cited by this paper
• Hodgkin cells accumulate mRNA for bcl-2.

  1995cited by this paper
• Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases.

  1994cited by this paper
• An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease.

  1993cited by this paper
• bcl-2 expression in Hodgkin's disease. Correlation with the t(14;18) translocation and Epstein-Barr virus.

  1993cited by this paper
• NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis.

  1992cited by this paper
• A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party.

  1992cited by this paper
• Recurrent laryngeal nerve palsy after thyroid and parathyroid surgery. Experience from Lund University.

  1992cited by this paper
• Chromosomal abnormalities in patients with Hodgkin's disease: evidence for frequent involvement of the 14q chromosomal region but infrequent bcl-2 gene rearrangement in Reed-Sternberg cells.

  1992cited by this paper
• Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.

  1992cited by this paper
• Direct sequence analysis of the t(14;18) chromosomal translocation in Hodgkin's disease.

  1992cited by this paper
• Absence of t(14;18) major and minor breakpoints and of Bcl-2 protein overproduction in Reed-Sternberg cells of Hodgkin's disease.

  1991cited by this paper
• Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)

  1991cited by this paper
• Involvement of the bcl-2 gene in Hodgkin's disease.

  1990cited by this paper
• Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.

  1990cited by this paper
• bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.

  1989cited by this paper
• Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

  1986cited by this paper
• Twenty years of MOPP therapy for Hodgkin's disease.

  1986cited by this paper
• Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.

  1984cited by this paper
• Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

  1975cited by this paper
• [Cytogenetics in Hodgkin's disease].

  1973cited by this paper
• Regression models and life tables (with discussion

  1972cited by this paper
• Report of the Committee on Hodgkin's Disease Staging Classification.

  1971cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Hodgkin’s Disease

  1933cited by this paper

• The art of war: using genetic insights to understand and harness radiation sensitivity in hematologic malignancies

  2025cites this paper
• SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study

  2024cites this paper
• Laying the groundwork for the Biobank of Rare Malignant Neoplasms at the service of the Hellenic Network of Precision Medicine on Cancer

  2022cites this paper
• Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma

  2022cites this paper
• Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma.

  2021cites this paper
• Ttherapy Iin Cclassical Hodgkin Lymphoma

  2021cites this paper
• Nodular sclerosis Hodgkin lymphoma

  2021cites this paper
• Mixed cellularity Hodgkin lymphoma

  2021cites this paper
• Clinicopathological Features of Syncytial Variant Nodular Sclerosis Hodgkin lymphoma.

  2021cites this paper
• Classic Hodgkin Lymphoma - Old Disease, New Directions: An Update on Pathology, Molecular Features and Biological Prognostic Markers.

  2021cites this paper
• Prognostic value of Bcl2 and p53 in Hodgkin lymphoma: A systematic review and meta-analysis.

  2021cites this paper
• Expression of the novel tumour suppressor sterile alpha motif and HD domain‐containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma

  2021cites this paper
• Histology of pediatric classic Hodgkin lymphoma: From diagnosis to prognostic stratification

  2020cites this paper
• Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis

  2019cites this paper
• American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.

  2019cites this paper
• Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies

  2019cites this paper
• Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma.

  2018cites this paper
• Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-γ expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications

  2017cites this paper
• Prognostic factors in Hodgkin lymphoma.

  2016cites this paper
• Identificación de marcadores de utilidad diagnóstica y pronóstica en linfoma B de célula grande agresivo: = Identification of diagnostic and prognostic markers in aggressive large B cell lymphoma

  2015cites this paper
• Advanced Classical Hodgkin Lymphoma: new insights in prognostic factors using gene and microRNA expression signatures

  2014influential citation
• Expression of the active caspase-3 in children and adolescents with classical Hodgkin lymphoma.

  2014cites this paper
• Genetic and molecular targets in lymphoma: implications for prognosis and treatment.

  2014cites this paper
• LGALS3 as a prognostic factor for classical Hodgkin’s lymphoma

  2014cites this paper
• Hodgkin Lymphoma: Pathology, Pathogenesis, and a Plethora of Potential Prognostic Predictors

  2014cites this paper
• Prognostic Factors in Hodgkin Lymphoma

  2014cites this paper
• Pathology of Non-Hodgkin’s and Hodgkin’s Lymphomas

  2013cites this paper
• Refractory Hodgkin Lymphoma

  2013cites this paper
• Matrix Metalloproteinase-9 Expression by Hodgkin-Reed-Sternberg Cells Is Associated with Reduced Overall Survival in Young Adult Patients with Classical Hodgkin Lymphoma

  2013cites this paper
• MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma

  2013cites this paper
• Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years.

  2013cites this paper
• Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival.

  2013cites this paper
• Lymphocyte-Rich Classical Hodgkin Lymphoma

  2013cites this paper
• Lymphocyte-Depleted Hodgkin Lymphoma

  2013cites this paper
• The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment

  2012cites this paper
• Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications

  2012cites this paper
• Prognostic Significance of Bcl-2, Tumor-Associated Macrophages, and Total Neoplastic and Inflammatory Lymph Node Involvement in Advanced Stage Classical Hodgkin’s Lymphoma

  2012cites this paper
• Analysis of NF-κB Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome-A Children's Oncology Group Study.

  2012cites this paper
• Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols

  2012cites this paper
• Radiotherapy for Hodgkin's lymphoma: too hard to die?

  2012cites this paper
• miRNAs at the crossroad between hematopoietic malignancies and autoimmune pathogenesis.

  2012cites this paper
• Hodgkin's Lymphoma: From Tumor Microenvironment to Immunotherapeutic Approach - Body's Own Power Protection Challenges

  2012cites this paper
• EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation

  2012cites this paper
• IMMUNOHISTOCHEMICAL EXPRESSION OF EPSTEIN BARR VIRUS ANTIGEN LATENT MEMBRANE PROTEIN-1 AND BCL-2 IN CLASSICAL HODGKIN LYMPHOMA

  2012influential citation
• Advances in Classical Hodgkin Lymphoma Biology: New Prognostic Factors and Outcome Prediction Using Gene Expression Signatures

  2012cites this paper
• Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding.

  2012cites this paper
• Primary Refractory and Relapsed Classical Hodgkin Lymphoma - Significance of Differential CD15 Expression in Hodgkin-Reed-Sternberg Cells

  2012cites this paper
• Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.

  2012cites this paper
• Cytochrome P450 17 (CYP17) is involved in endometrial cancinogenesis through apoptosis and invasion pathways

  2011cites this paper
• Hodgkin lymphoma: epidemiology, histopathology, staging, and treatment

  2011influential citation
• The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis.

  2011cites this paper
• Current concepts and controversies in the management of early stage Hodgkin lymphoma

  2011cites this paper
• Glioma-associated oncogene homologue 3, a hedgehog transcription factor, is highly expressed in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.

  2011cites this paper
• Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymhoma.

  2011cites this paper
• classical Hodgkin lymphoma A molecular risk score based on 4 functional pathways for advanced

  2011cites this paper
• Fatores genéticos e ambientais na patogênese, constituição do microambiente tumoral e prognóstico clínico do linfoma de hodgkin pediátrico

  2011cites this paper
• MicroRNAs in breast cancer

  2011cites this paper
• Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma.

  2010cites this paper
• Hodgkin lymphoma in Iceland A clinico-pathological study

  2010influential citation
• Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma.

  2010cites this paper
• High Dose Chemoradiotherapy and ASCT May Overcome the Prognostic Importance of Biologic Markers in Relapsed/Refractory Hodgkin Lymphoma

  2010cites this paper
• Expression and prognostic significance of cox-2 and p-53 in hodgkin lymphomas: a retrospective study

  2010cites this paper
• Cell cycle characteristics and Epstein–Barr virus are differentially associated with aggressive and non-aggressive subsets of Hodgkin lymphoma in pediatric patients

  2010cites this paper
• A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma.

  2010cites this paper
• Monoclonal B cells detected in autologous PBSC grafts from patients with classical Hodgkin lymphoma: impact on relapse and survival following transplantation

  2010cites this paper
• Hodgkin's lymphoma therapy: past, present, and future

  2010cites this paper
• A TaqMan Low-Density Array to Predict Outcome in Advanced Hodgkin's Lymphoma Using Paraffin-Embedded Samples

  2009cites this paper
• Hodgkin lymphoma ( HL ) is a malignant proliferation of Reed-Sternberg cells and their variants , Hodgkin cells , in an inflammatory cellular Low apoptotic index & bak expression in EbV-associated childhood classical Hodgkin lymphoma

  2009cites this paper
• BH3-mimetics – the solution to chemoresistance?

  2009cites this paper
• The roles of microRNA in cancer and apoptosis

  2009cites this paper
• Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737

  2009cites this paper
• Low apoptotic index & bak expression in EBV-associated childhood classical Hodgkin lymphoma.

  2009cites this paper
• New biologic and therapeutic insights in Hodgkin's lymphoma

  2009cites this paper
• Bcl-2 expression in Hodgkin's lymphoma progression.

  2008cites this paper
• Role of immunoexpression of nitric oxide synthases by Hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical Hodgkin lymphoma

  2008cites this paper
• Tumor-Infiltrated Immune Response Correlates with Alterations in the Apoptotic and Cell Cycle Pathways in Hodgkin and Reed-Sternberg Cells

  2008cites this paper
• Topoisomerase IIα Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma

  2008cites this paper
• Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment

  2008cites this paper
• The expression of Ki-67 and Bcl-2 in hodgkin’s lymphoma: Correlation with the international prognostic score and bulky disease

  2007cites this paper
• Larger than life: Mitochondria and the Bcl-2 family.

  2007cites this paper
• Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas.

  2007cites this paper
• The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression.

  2007cites this paper
• HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.

  2007cites this paper
• ORIGINAL ARTICLE / RESEARCH

  2007cites this paper
• Novel small-molecule therapy of Hodgkin lymphoma

  2007cites this paper
• Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.

  2007cites this paper
• Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease.

  2006cites this paper
• Immunohistochemical Expression of p53, bcl-2, and p21waf1 in 48 Argentinean Children With Non-Hodgkin Lymphoma

  2006cites this paper
• Pathobiology of Classical Hodgkin Lymphoma

  2006cites this paper
• Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis

  2006cites this paper
• Expression of cyclooxygenase-2 in Hodgkin's lymphoma:its role in cell proliferation and angiogenesis

  2006cites this paper
• outcome of classical Hodgkin lymphoma Tumor microenvironment and mitotic checkpoint are key factors in the

  2006cites this paper
• Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome.

  2005cites this paper
• Expression of BAFF-R (BR3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody

  2005cites this paper
• Analysis of the Bcl-2 and p53 protein expression in the lymphoproliferative lesions in the upper Egypt

  2005cites this paper
• Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma.

  2005cites this paper
• Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications

  2005cites this paper
• The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma

  2005cites this paper
• Preclinical evaluation of antisense bcl‐2 as a chemosensitizer for patients with gastric carcinoma

  2004cites this paper
• Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group.

  2004cites this paper